A CLINICAL TRIAL TO STUDY THE EFFECT OF THE DRUG RASA CHENDURAM IN PATIENTS HAVING RHEUMATOID ARTHRITIS

EVALUATION OF RASA CHENDURAM FOR UTHIRAVAATHA SURONITHAM(RHEUMATOID ARTHRITIS)-AN OPEN CLINICAL STUDY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016562

Enrollment

Registered

2018-12-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: RASA CHENDURAM: 130 mg of Rasa chenduram is administrated orally once a day with Pepper powder for 48 days Control Intervention1: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18 to 50 years Both male and female Arthritis of 3 or more joints Morning stiffness more than 1 hour Symmetrical Arthritis Arthritis of hand joints Anti-Cyclic citrullinated Peptide (Anti CCP) Positive

Exclusion criteria

Exclusion criteria: Age below 18 and above 50 years Rheumatic fever Psoriatic arthritis Reiters arthritis Gouty arthritis Systemic Lupus Erythematosus Progressive systemic sclerosis Pregnant women and lactating mothers Any other serious systemic illness will be excluded clinically or based on available medical reports

Design outcomes

Primary

Measure	Time frame
Outcome is mainly assessed by reduction in clinical symptoms measured by Universal pain assessment(Visual analogue scale)Timepoint: 48 days	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Sabarmathi S

Government siddha medical college

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026